RAD51 and glioblastoma: In glioblastoma (GBM), pharmacological inhibition of FTO (e.g., using FB23-2) increases m6A modification on the target gene VEGFA, downregulating its expression and impairing DNA damage repair (e.g., sustaining γH2AX foci and reducing Rad51 recruitment).